{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.5","upperLimit":"87.4","value":"82.4"},{"groupId":"OG001","lowerLimit":"54.6","upperLimit":"74.4","value":"64.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment.\n\nCR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.\n\nStable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"OG000","title":"Everolimus + BSC"},{"description":"Participants received matching placebo once daily plus BSC during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period","id":"OG001","title":"Placebo + BSC"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients were analyzed according to the treatment arm and stratification factors they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"From randomization until end of treatment, assessed up to approximately 2.5 years","title":"Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}